U.S. Meibomian Gland Dysfunction Market is growing rapidly with ThermaMEDx introducing a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction

Dysfunction of any of these three glands can result in Meibomian gland dysfunction. A primary cause for this condition is not really the disease itself but rather the abnormal overproduction of sebum (the secreted liquid of glands). This is normally controlled by the hypothalamus-pituitary gland system which inhibits the secretion of oil. Rapidly increases the prevalence of meibomian gland dysfunction remains one of the critical factors aiding the development of the market. In fact, as per the Fellow of American College of Surgeons, meibomian gland disease, is one of the most common causes of dry eyes and around 50-70% of the elderly population has some degree of dry eye. Besides, as per the American Optometric Association’s study in 2017, over 16 million people in the U.S. were suffering from dry eye disease. Such factors can indeed stimulate growth of the U.S. meibomian gland dysfunction market.

When it comes to the drug type, Cyclosporine segment seems to be exhibiting positive traction in the U.S. meibomian gland dysfunction market. This is typically due to the fact that there is a rapid launch of novel products in the market. Recently, in August 2018, Sun Pharma received the U.S. Food and Drug Administration (FDA) approval for Cequa, indicated for increasing tear production in patients with dry eye disease. Recently, in April 2021, ThermaMEDx launched a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.

Secondary causes of Meibomian gland dysfunction are poor lid hygiene, fungal infections of unknown cause, and obstruction of drainage by the lymph nodes, which results in Meibomian glands becoming coated with a thin whitish epidermis. However, there are some factors that can potentially inhibit growth of the market in the near future. For instance, potential side effects of drugs used in the treatment of meibomian gland dysfunction could impede growth of the U.S. meibomian gland dysfunction market. Besides, challenges associated with disease diagnosis could limit the market growth in the near future.

To treat Meibomian gland dysfunction, one of its most important therapies is the use of therapeutic oils that have high therapeutic values such as avocado oil, macadamia oil, olive oil, jojoba oil, grape seed oil, sweet almond oil, lavender oil, and Maracuja passion fruit extract. Another key factor augmenting growth of the market is excessive exposure to mobile and computer screens. People who frequently use computers or video screens are at high risk of developing dry eye or meibomian gland dysfunction. Digital device usage has increased significantly in the recent past, which is leading to such eye-related disorders. Hence, these factors can stimulate growth of the U.S. meibomian gland dysfunction market.